

**Figure 1**

GATCAAACCTCTTTCCATTGAGAGTCCTCTGATTGAGATTTAATGTAAACATTTTGGAAGACAGTATTCAGAAAAAATTTCC  
TTAATAAAAATACAACCTGAGATCCTTCAAATATGAACTGGTTGGGGAATCTCCATTTTTCAATATTATTTCTTCTTTGTTTTTC  
TTGCTACGTATAATTATTAATATCCTGACTAGGTTGTGGTTGGAGGGTTATTACTTTTCATTTTACCATGCAGTCCAAATCTAAAC  
TGCTTCTACTGATGGTTTACAGCATTCTGAGATAAGAATGGTACATCTAGAGAACATTTGCCAAAGGCCTAAGCACAGCAAAGGAA  
AATAAACACAGAATATAATAAAATGAGATAATCTAGCTTAAACTATAACTTCCTCTTTAGAACTCCCAACCACATTTGGATC

sd-61572

Title: NUCLEIC ACID AND CORRESPONDING PROTEIN  
ENTITLED 101P3A41 USEFUL IN TREATMENT AND  
DETECTION OF CANCER

First Inventor: Daniel E. H. AFAR, et al

Application No.: To Be Assigned - Docket No. 511582002420

Sheet 2 of 50

FIG. 2A

```

          9          18          27          36          45          54
5'  CAG AGA GGC TGT ATT TCA GTG CAG CCT GCC AGA CCT CTT CTG GAG GAA GAC TGG
    ---
          63          72          81          90          99          108
    ACA AAG GGG GTC ACA CAT TCC TTC CAT ACG GTT GAG CCT CTA CCT GCC TGG TGC
    ---

          117          126          135          144          153          162
    TGG TCA CAG TTC AGC TTC ATG ATG GTG GAT CCC AAT GGC AAT GAA TCC AGT
    ---
                                M  M  V  D  P  N  G  N  E  S  S

          171          180          189          198          207          216
    GCT ACA TAC TTC ATC CTA ATA GGC CTC CCT GGT TTA GAA GAG GCT CAG TTC TGG
    ---
    A  T  Y  F  I  L  I  G  L  P  G  L  E  E  A  Q  F  W

          225          234          243          252          261          270
    TTG GCC TTC CCA TTG TGC TCC CTC TAC CTT ATT GCT GTG CTA GGT AAC TTG ACA
    ---
    L  A  F  P  L  C  S  L  Y  L  I  A  V  L  G  N  L  T

          279          288          297          306          315          324
    ATC ATC TAC ATT GTG CGG ACT GAG CAC AGC CTG CAT GAG CCC ATG TAT ATA TTT
    ---
    I  I  Y  I  V  R  T  E  H  S  L  H  E  P  M  Y  I  F

          333          342          351          360          369          378
    CTT TGC ATG CTT TCA GGC ATT GAC ATC CTC ATC TCC ACC TCA TCC ATG CCC AAA
    ---
    L  C  M  L  S  G  I  D  I  L  I  S  T  S  S  M  P  K

          387          396          405          414          423          432
    ATG CTG GCC ATC TTC TGG TTC AAT TCC ACT ACC ATC CAG TTT GAT GCT TGT CTG
    ---
    M  L  A  I  F  W  F  N  S  T  T  I  Q  F  D  A  C  L

          441          450          459          468          477          486
    CTA CAG ATT TTT GCC ATC CAC TCC TTA TCT GGC ATG GAA TCC ACA GTG CTG CTG
    ---
    L  Q  I  F  A  I  H  S  L  S  G  M  E  S  T  V  L  L

          495          504          513          522          531          540
    GCC ATG GCT TTT GAC CGC TAT GTG GCC ATC TGT CAC CCA CTG CGC CAT GCC ACA
    ---
    A  M  A  F  D  R  Y  V  A  I  C  H  P  L  R  H  A  T

          549          558          567          576          585          594
    GTA CTT ACG TTG CCT CGT GTC ACC AAA ATT GGT GTG GCT GCT GTG GTG CGG GGG
    ---
    V  L  T  L  P  R  V  T  K  I  G  V  A  A  V  V  R  G

          603          612          621          630          639          648
    GCT GCA CTG ATG GCA CCC CTT CCT GTC TTC ATC AAG CAG CTG CCC TTC TGC CGC
    ---
    A  A  L  M  A  P  L  P  V  F  I  K  Q  L  P  F  C  R
```

Title: NUCLEIC ACID AND CORRESPONDING PROTEIN  
ENTITLED 101P3A41 USEFUL IN TREATMENT AND  
DETECTION OF CANCER

First Inventor: Daniel E. H. AFAR, et al

Application No.: To Be Assigned - Docket No. 511582002420

Sheet 3 of 50

FIG. 2B

|      |     |     |      |     |     |      |     |     |      |     |     |      |     |     |      |     |     |
|------|-----|-----|------|-----|-----|------|-----|-----|------|-----|-----|------|-----|-----|------|-----|-----|
| 657  |     |     | 666  |     |     | 675  |     |     | 684  |     |     | 693  |     |     | 702  |     |     |
| TCC  | AAT | ATC | CTT  | TCC | CAT | TCC  | TAC | TGC | CTA  | CAC | CAA | GAT  | GTC | ATG | AAG  | CTG | GCC |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| S    | N   | I   | L    | S   | H   | S    | Y   | C   | L    | H   | Q   | D    | V   | M   | K    | L   | A   |
| 711  |     |     | 720  |     |     | 729  |     |     | 738  |     |     | 747  |     |     | 756  |     |     |
| TGT  | GAT | GAT | ATC  | CGG | GTC | AAT  | GTC | GTC | TAT  | GGC | CTT | ATC  | GTC | ATC | ATC  | TCC | GCC |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| C    | D   | D   | I    | R   | V   | N    | V   | V   | Y    | G   | L   | I    | V   | I   | I    | S   | A   |
| 765  |     |     | 774  |     |     | 783  |     |     | 792  |     |     | 801  |     |     | 810  |     |     |
| ATT  | GGC | CTG | GAC  | TCA | CTT | CTC  | ATC | TCC | TTC  | TCA | TAT | CTG  | CTT | ATT | CTT  | AAG | ACT |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| I    | G   | L   | D    | S   | L   | L    | I   | S   | F    | S   | Y   | L    | L   | I   | L    | K   | T   |
| 819  |     |     | 828  |     |     | 837  |     |     | 846  |     |     | 855  |     |     | 864  |     |     |
| GTG  | TTG | GGC | TTG  | ACA | CGT | GAA  | GCC | CAG | GCC  | AAG | GCA | TTT  | GGC | ACT | TGC  | GTC | TCT |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| V    | L   | G   | L    | T   | R   | E    | A   | Q   | A    | K   | A   | F    | G   | T   | C    | V   | S   |
| 873  |     |     | 882  |     |     | 891  |     |     | 900  |     |     | 909  |     |     | 918  |     |     |
| CAT  | GTG | TGT | GCT  | GTG | TTC | ATA  | TTC | TAT | GTA  | CCT | TTC | ATT  | GGA | TTG | TCC  | ATG | GTG |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| H    | V   | C   | A    | V   | F   | I    | F   | Y   | V    | P   | F   | I    | G   | L   | S    | M   | V   |
| 927  |     |     | 936  |     |     | 945  |     |     | 954  |     |     | 963  |     |     | 972  |     |     |
| CAT  | CGC | TTT | AGC  | AAG | CGG | CGT  | GAC | TCT | CCG  | CTG | CCC | GTC  | ATC | TTG | GCC  | AAT | ATC |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| H    | R   | F   | S    | K   | R   | R    | D   | S   | P    | L   | P   | V    | I   | L   | A    | N   | I   |
| 981  |     |     | 990  |     |     | 999  |     |     | 1008 |     |     | 1017 |     |     | 1026 |     |     |
| TAT  | CTG | CTG | GTT  | CCT | CCT | GTG  | CTC | AAC | CCA  | ATT | GTC | TAT  | GGA | GTG | AAG  | ACA | AAG |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| Y    | L   | L   | V    | P   | P   | V    | L   | N   | P    | I   | V   | Y    | G   | V   | K    | T   | K   |
| 1035 |     |     | 1044 |     |     | 1053 |     |     | 1062 |     |     | 1071 |     |     | 1080 |     |     |
| GAG  | ATT | CGA | CAG  | CGC | ATC | CTT  | CGA | CTT | TTC  | CAT | GTG | GCC  | ACA | CAC | GCT  | TCA | GAG |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| E    | I   | R   | Q    | R   | I   | L    | R   | L   | F    | H   | V   | A    | T   | H   | A    | S   | E   |
| 1089 |     |     | 1098 |     |     | 1107 |     |     | 1116 |     |     | 1125 |     |     | 1134 |     |     |
| CCC  | TAG | GTG | TCA  | GTG | ATC | AAA  | CTT | CTT | TTC  | CAT | TCA | GAG  | TCC | TCT | GAT  | TCA | GAT |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| P    | *   |     |      |     |     |      |     |     |      |     |     |      |     |     |      |     |     |
| 1143 |     |     | 1152 |     |     | 1161 |     |     | 1170 |     |     | 1179 |     |     | 1188 |     |     |
| TTT  | AAT | GTT | AAC  | ATT | TTG | GAA  | GAC | AGT | ATT  | CAG | AAA | AAA  | AAT | TTC | CTT  | AAT | AAA |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| 1197 |     |     | 1206 |     |     | 1215 |     |     | 1224 |     |     | 1233 |     |     | 1242 |     |     |
| AAA  | TAC | AAC | TCA  | GAT | CCT | TCA  | AAT | ATG | AAA  | CTG | GTT | GGG  | GAA | TCT | CCA  | TTT | TTT |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| 1251 |     |     | 1260 |     |     | 1269 |     |     | 1278 |     |     | 1287 |     |     | 1296 |     |     |
| CAA  | TAT | TAT | TTT  | CTT | CTT | TGT  | TTT | CTT | GCT  | ACA | TAT | AAT  | TAT | TAA | TAC  | CCT | GAC |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |
| 1305 |     |     | 1314 |     |     | 1323 |     |     | 1332 |     |     | 1341 |     |     | 1350 |     |     |
| TAG  | GTT | GTG | GTT  | GGA | GGG | TTA  | TTA | CTT | TTC  | ATT | TTA | CCA  | TGC | AGT | CCA  | AAT | CTA |
| ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- | ---  | --- | --- |

Title: NUCLEIC ACID AND CORRESPONDING PROTEIN  
ENTITLED 101P3A41 USEFUL IN TREATMENT AND  
DETECTION OF CANCER

First Inventor: Daniel E. H. AFAR, et al

Application No.: To Be Assigned - Docket No. 511582002420

Sheet 4 of 50

FIG. 2C

|             |             |             |             |             |             |
|-------------|-------------|-------------|-------------|-------------|-------------|
| 1359        | 1368        | 1377        | 1386        | 1395        | 1404        |
| AAC TGC TTC | TAC TGA TGG | TTT ACA GCA | TTC TGA GAT | AAG AAT GGT | ACA TCT AGA |
| 1413        | 1422        | 1431        | 1440        | 1449        | 1458        |
| GAA CAT TTG | CCA AAG GCC | TAA GCA CGG | CAA AGG AAA | ATA AAC ACA | GAA TAT AAT |
| 1467        | 1476        | 1485        | 1494        | 1503        | 1512        |
| AAA ATG AGA | TAA TCT AGC | TTA AAA CTA | TAA CTT CCT | CTT CAG AAC | TCC CAA CCA |
| 1521        | 1530        | 1539        | 1548        | 1557        | 1566        |
| CAT TGG ATC | TCA GAA AAA | TGC TGT CTT | CAA AAT GAC | TTC TAC AGA | GAA GAA ATA |
| 1575        | 1584        | 1593        | 1602        | 1611        | 1620        |
| ATT TTT CCT | CTG GAC ACT | AGC ACT TAA | GGG GAA GAT | TGG AAG TAA | AGC CTT GAA |
| 1629        | 1638        | 1647        | 1656        | 1665        | 1674        |
| AAG AGT ACA | TTT ACC TAC | GTT AAT GAA | AGT TGA CAC | ACT GTT CTG | AGA GTT TTC |
| 1683        | 1692        | 1701        | 1710        | 1719        | 1728        |
| ACA GCA TAT | GGA CCC TGT | TTT TCC TAT | TTA ATT TTC | TTA TCA ACC | CTT TAA TTA |
| 1737        | 1746        | 1755        | 1764        | 1773        | 1782        |
| GGC AAA GAT | ATT ATT AGT | ACC CTC ATT | GTA GCC ATG | GGA AAA TTG | ATG TTC AGT |
| 1791        | 1800        | 1809        | 1818        | 1827        | 1836        |
| GGG GAT CAG | TGA ATT AAA | TGG GGT CAT | ACA AGT ATA | AAA ATT AAA | AAA AAA AAA |
| 1845        | 1854        | 1863        | 1872        | 1881        | 1890        |
| GAC TTC ATG | CCC AAT CTC | ATA TGA TGT | GGA AGA ACT | GTT AGA GAG | ACC AAC AGG |
| 1899        | 1908        | 1917        | 1926        | 1935        | 1944        |
| GTA GTG GGT | TAG AGA TTT | CCA GAG TCT | TAC ATT TTC | TAG AGG AGG | TAT TTA ATT |
| 1953        | 1962        | 1971        | 1980        | 1989        | 1998        |
| TCT TCT CAC | TCA TCC AGT | GTT GTA TTT | AGG AAT TTC | CTG GCA ACA | GAA CTC ATG |
| 2007        | 2016        | 2025        | 2034        | 2043        | 2052        |
| GCT TTA ATC | CCA CTA GCT | ATT GCT TAT | TGT CCT GGT | CCA ATT GCC | AAT TAC CTG |
| 2061        | 2070        | 2079        | 2088        | 2097        | 2106        |
| TGT CTT GGA | AGA AGT GAT | TTC TAG GTT | CAC CAT TAT | GGA AGA TTC | TTA TTC AGA |
| 2115        | 2124        | 2133        | 2142        | 2151        | 2160        |
| AAG TCT GCA | TAG GGC TTA | TAG CAA GTT | ATT TAT TTT | TAA AAG TTC | CAT AGG TGA |
| 2169        | 2178        | 2187        | 2196        | 2205        | 2214        |
| TTC TGA TAG | GCA GTG AGG | TTA GGG AGC | CAC CAG TTA | TGA TGG GAA | GTA TGG AAT |
| 2223        | 2232        | 2241        | 2250        | 2259        | 2268        |
| GGC AGG TCT | TGA AGA TAA | CAT TGG CCT | TTT GAG TGT | GAC TCG TAG | CTG GAA AGT |
| 2277        | 2286        | 2295        | 2304        | 2313        | 2322        |
| GAG GGA ATC | TTC AGG ACC | ATG CTT TAT | TTG GGG CTT | TGT GCA GTA | TGG AAC AGG |
| 2331        | 2340        | 2349        | 2358        | 2367        | 2376        |
| GAC TTT GAG | ACC AGG AAA | GCA ATC TGA | CTT AGG CAT | GGG AAT CAG | GCA TTT TTG |

Title: NUCLEIC ACID AND CORRESPONDING PROTEIN  
ENTITLED 101P3A41 USEFUL IN TREATMENT AND  
DETECTION OF CANCER

First Inventor: Daniel E. H. AFAR, et al

Application No.: To Be Assigned - Docket No. 511582002420

Sheet 5 of 50

FIG. 2D

|   |      |      |      |      |      |
|---|------|------|------|------|------|
| 2385  | 2394 | 2403 | 2412 | 2421 | 2430 |
| CTT CTG AGG GGC TAT TAC CAA GGG TTA ATA GGT TTC ATC TTC AAC AGG ATA TGA |      |      |      |      |      |
| 2439  | 2448 | 2457 | 2466 | 2475 | 2484 |
| CAA CAG TGT TAA CCA AGA AAC TCA AAT TAC AAA TAC TAA AAC ATG TGA TCA TAT |      |      |      |      |      |
| 2493  | 2502 | 2511 | 2520 | 2529 | 2538 |
| ATG TGG TAA GTT TCA TTT TCT TTT TCA ATC CTC AGG TTC CCT GAT ATG GAT TCC |      |      |      |      |      |
| 2547  | 2556 | 2565 | 2574 | 2583 | 2592 |
| TAT AAC ATG CTT TCA TCC CCT TTT GTA ATG GAT ATC ATA TTT GGA AAT GCC TAT |      |      |      |      |      |
| 2601  | 2610 | 2619 | 2628 | 2637 | 2646 |
| TTA ATA CTT GTA TTT GCT GCT GGA CTG TAA GCC CAT GAG GGC ACT GTT TAT TAT |      |      |      |      |      |
| 2655  | 2664 | 2673 | 2682 | 2691 | 2700 |
| TGA ATG TCA TCT CTG TTC ATC ATT GAC TGC TCT TTG CTC ATC ATT GAA TCC CCC |      |      |      |      |      |
| 2709  | 2718 | 2727 | 2736 | 2745 | 2754 |
| AGC AAA GTG CCT AGA ACA TAA TAG TGC TTA TGC TTG ACA CCG GTT ATT TTT CAT |      |      |      |      |      |
| 2763  | 2772 | 2781 | 2790 | 2799 | 2808 |
| CAA ACC TGA TTC CTT CTG TCC TGA ACA CAT AGC CAG GCA ATT TTC CAG CCT TCT |      |      |      |      |      |
| 2817  | 2826 | 2835 | 2844 | 2853 | 2862 |
| TTG AGT TGG GTA TTA TTA AAT TCT GGC CAT TAC TTC CAA TGT GAG TGG AAG TGA |      |      |      |      |      |
| 2871  | 2880 | 2889 | 2898 | 2907 | 2916 |
| CAT GTG CAA TTT CTA TAC CTG GCT CAT AAA ACC CTC CCA TGT GCA GCC TTT CAT |      |      |      |      |      |
| 2925  | 2934 | 2943 | 2952 | 2961 | 2970 |
| GTT GAC ATT AAA TGT GAC TTG GGA AGC TAT GTG TTA CAC AGA GTA AAT CAC CAG |      |      |      |      |      |
| 2979  | 2988 | 2997 | 3006 | 3015 | 3024 |
| AAG CCT GGA TTT CTG AAA AAA CTG TGC AGA GCC AAA CCT CTG TCA TTT GCA ACT |      |      |      |      |      |
| 3033  | 3042 | 3051 | 3060 | 3069 | 3078 |
| CCC ACT TGT ATT TGT ACG AGG CAG TTG GAT AAG TGA AAA ATA AAG TAC TAT TGT |      |      |      |      |      |
| 3087  | 3096 | 3105 | 3114 | 3123 | 3132 |
| GTC AAG AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA     |      |      |      |      |      |

AAA A 3'

----

Figure 3: Protein Sequence for 101P3A11.

MVDPNGNESSATYFILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFLCMLSGIDILI  
STSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSZSGMESTVLLAMAFDRYVAICHPLRHATVLTLPRTKIGV  
AAVVRGAALMAPLPVFIKQLPFCRSNILSHSYCLHQDVMKLACDDIRVNVVYGLIVIIISAIGLDSLLISFSYL  
LILKTVLGLTREAQAKAFGTCVSHVCAVFIFYVFFIGLSMVHFRFSKRRDSPLPVILANIYLLVPPVLNPIVYG  
VKTKEIRQRILRLFHVATHASEP

sd-61572

Title: NUCLEIC ACID AND CORRESPONDING PROTEIN  
ENTITLED 101P3A41 USEFUL IN TREATMENT AND  
DETECTION OF CANCER

First Inventor: Daniel E. H. AFAR, et al

Application No.: To Be Assigned - Docket No. 511582002420

Sheet 7 of 50

Figure 4

Alignment of 101P3A11 (Sbjct) with mouse olfactory receptor S25 (Query)

Query: 34 GNYTVVTEFILLGLTDDITVSVILFVMFLIVSVTLMGNLNIIVLIRTSPQLHTPMYLFL 93  
GN + T FIL+GL L +Y + ++GNL II ++RT LH PMY+FL  
Sbjct: 6 GNESSATYFILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFL 65

Query: 94 SHLAFLDIGYSSSVTPIMLRGFLRKGTFFIPVAGCVAQLCIVVAFGTSESFLLASMAYDRY 153  
L+ +DI S+S P ML F T I C+ Q+ + + ES +L +MA+DRY  
Sbjct: 66 CMLSGIDILISTSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSLSGMESTVLLAMAFDRY 125

Query: 154 VAICSPLLYSTQMSSTVCILLVGTSYLGGWVNAWIFTGCSLNL\$FCGPNKINHFFCDYSP 213  
VAIC PL ++T ++ + + + G L FC N ++H +C +  
Sbjct: 126 VAICHPLRHATVLTLPRTKIGVAAVVRGAALMAPLPVFIKQLPFCRSNILSHSYCLHQD 185

Query: 214 LLKLSCSHDFSFEVIPAISSGSIIVVTVFIIALSIVYILVSILKMRSTEGRQKAFSTCTS 273  
++KL+C V I S I + +I+ SY+ IL ++L + + E + KAF TC S  
Sbjct: 186 VMKLACDDIRVNVVYGLIVIIISAIGLDSLLISFSYLLILKTVLGL-TREAQAKAFGTCVS 244

Query: 274 HLTAVTLFFGTITFIYVMPQSSYSTDQNK----VVSVFYTVVIPMLNPLIYSFRNKEVKE 329  
H+ AV +F+ + FI + +S ++ +++ Y +V P+LNP++Y + KE+++  
Sbjct: 245 HVCAVFIFY--VPFIGLSMVHRFSKRDSPLPVILANIYLLVPPVLNPIVYGVKTKEIRQ 302

Query: 330 AMKKL 334  
+ +L  
Sbjct: 303 RILRL 307

Figure 5:  
101P3A11 Hydrophilicity profile  
(Hopp T.P., Woods K.R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828)






Figure 6:  
101P3A11 Hydropathicity Profile  
(Kyte J., Doolittle R.F., 1982. J. Mol. Biol. 157:105-132)




Figure 7:  
101P3A11 % Accessible Residues Profile  
(Janin J., 1979. Nature 277:491-492)




Figure 8:  
101P3A11 Average Flexibility Profile  
(Bhaskaran R., Ponnuswamy P.K., 1988.  
Int. J. Pept. Protein Res. 32:242-255)




Figure 9:  
101P3A11 Beta-turn Profile  
(Deleage, G., Roux B. 1987. Protein Engineering 1:289-294)




Figure 10A. Expression of 101P3A11 by RT-PCR

- VP1 (Kidney, Lung, Liver)
- VP2 (Pancreas, Colon, Stomach)
- Prostate xenograft Pool
- Prostate Cancer Pool
- Kidney Cancer Pool
- Colon Cancer Pool
- Breast Cancer Pool
- Metastasis Pool
- H2O






Figure 10B



**Figure 11. Expression of 101P3A11 in Human Patient Cancer Specimens**



10µg total RNA/per lane from a pool of 3 tumors as follows:

- Prostate Cancer Pool* = gleason 6, 8, 9
- Kidney Cancer Pool* = grade 2, 2, 3
- Colon Cancer Pool* = stage II, III, IV
- Breast Cancer Pool* = grade 1, 2, 3
- Metastasis Pool* = colon to lung, colon to liver, ovary to fall. tube

*NP* = Normal Prostate  
*NB* = Normal Bladder  
*NK* = Normal Kidney  
*NC* = Normal Colon

Figure 12A






Figure 12B and 12C




Figure 12D and 12E




Figure 13. Expression of 101P3A11 in Colon Cancer Patient Specimens





Figure 14. Expression of 101P3A11 in Kidney Cancer Patient Specimens



**Figure 15A-15C. Androgen Regulation of 101P3A11 in Tissue Culture Cells**






Figure 16. Androgen Regulation of 101P3A11 *In Vivo*




**Figure 17. Expression and Detection of 101P3A11(159-202)-  
psecFc Fusion Protein**





**Figure 18. Expression of 101P3A11 in 300.19 Cells**





*intra*    *inter*    *extra*    *contra*    *pro*    *per*    *super*    *sub*    *infra*    *trans*






Figure 19B-19C. Transmembrane prediction of 101P3A11

19B



19C



**Figure 20. Expression of 101P3A11 in NIH-3T3 Tumors**






Figure 21: 101P3A11 Induces Tumor Formation of 3T3 Cells



•Injection of 10<sup>6</sup> 3T3-neo, 3T3-Ras or 3T3-101P3A11 cells subcutaneously into SCID mice revealed that 6/6 3T3-Ras-injected mice formed tumors, 6/6 3T3-101P3A11- injected mice formed tumors, and 0/6 3T3-neo-injected mice formed tumors.

Figure 22: PTX Reduces the *in vivo* Growth of 3T3-101P3A11 Tumors



- Pertussis toxin inhibits the sub-cutaneous growth of 3T3-101P3A11 tumors in SCID mice.
- The inhibitory activity of pertussis toxin occurs in a dose dependent manner.

Figure 23: Alignment of 10IP3A11-PHOR-1 with the rat GPCR RA1C (gi|3420759).

Identities = 179/299 (59%), Positives = 231/299 (76%), Gaps = 1/299 (0%)

```

PHOR: 14  FILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFLCMLSGIDI 73
          F+LIG+PGLEEA FW  FPL S+Y +A+ GN  +++IVRTE SLH PMY+FLCML+ ID+
RA1C: 11  FMLIGIPGLEEAHFWFGFPLLSMYAVALFGNCIVVFIVRTERS LHAPMYLFLCMLAAIDL 70

PHOR: 74  LISTSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSLSGMESTVLLAMAFDRYVAICHPLR 133
          +STS+MPK+LA+FWF+S  I FDACL Q+F IH+LS +EST+LLAMAFDRYVAICHPLR
RA1C: 71  ALSTSTMPKILALFWFDSREITFDACLAQMFFIHALSAESTILLAMAFDRYVAICHPLR 130

PHOR: 134 HATVLTLPRTVKIGVAAVVRGAALMAPLPVFIKQLPFCRSNILSHSYCLHQDVMKLACDD 193
          HA VL      +IG+ A+VRG+  PLP+ IK+L FC SN+LSHSYC+HQDVMKLA  D
RA1C: 131 HAAVLNNTVTQIGMVALVRGSLFFFPLPLLIKRLAFCHSNVLSHSYCVHQDVMKLAYTD 190

PHOR: 194 IRNVVYGLIIVIISAIGLDSLLISFSYLLILKTVLGL-TREAQAKAFGTCVSHVCAVFIF 252
          NVVYGL  I+  +G+D + IS SY LI++ VL L ++  +AKAFGTCVSH+  V  F
RA1C: 191 TLPNVVYGLTAILLVMGVDVMFISLSYFLIIRAVLQLPSKSERAKAFGTCVSHIGVVLA 250

PHOR: 253 YVPFIGLSMVHRFSKRRDSPLPVILANIYLLVPPVLNPIVYGVKTKAIRQLRFLHVA 311
          YVP IGLS+VHRF  D  + V++ ++YLL+PPV+NPI+YG KTK+IR R+L +F ++
RA1C: 251 YVPLIGLSVVHRFGNSLDPIVHVLMDVYLLLPVINPIIYGAKTKQIRTRVLAMFKIS 309

```

Figure 24: Alignment of 101P3A11-PHOR-1 with the human prostate specific GPCR. (gi|13540539)

Identities = 179/299 (59%), Positives = 233/299 (77%), Gaps = 1/299 (0%)

```

PHOR: 14  FILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFLCMLSGIDI 73
          F+LIG+PGLE+A FW+ FPL S+Y++A+ GN +++IVRTE SLH PMY+FLCML+ ID+
GPCR: 11  FVLIGIPGLEKAHFWVGFPLLSMYVVAMFGNCIVVFIVRTERS LHAPMYLFLCMLAAIDL 70

PHOR: 74  LISTSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSLSGMESTVLLAMAFDRYVAICHPLR 133
          +STS+MPK+LA+FWF+S I F+ACL Q+F IH+LS +EST+LLAMAFDRYVAICHPLR
GPCR: 71  ALSTSTMPKILALFWFDSREISFEACLTQMFFIHALSAIESTILLAMAFDRYVAICHPLR 130

PHOR: 134 HATVLTLPRTVKIGVAAVVRGAALMAPLPVFIKQLPFCRSNILSHSYCLHQDVMKLACDD 193
          HA VL +IG+ AVVRG+ PLP+ IK+L FC SN+LSHSYC+HQDVMKLA D
GPCR: 131 HAAVLNNTVTQAQIGIVAVVRGSLFFFPLPLLIKRLAFCHSNVLSHSYCVHQDVMKLAYAD 190

PHOR: 194 IRVNVVYGLLIVIIISAIGLDSLLISFSYLLILKTVLGL-TREAQAKAFGTCVSHVCAVFIF 252
          NVVYGL I+ +G+D + IS SY LI++TVL L ++ +AKAFGTCVSH+ V F
GPCR: 191 TLPNVVYGLTAILLVMGVDVMFISLSYFLIIRTVLQLPSKSERAKAFGTCVSHIGVVLAFL 250

PHOR: 253 YVPFIGLSMVHRFSKRRDSPLPVILANIYLLVPPVLNPIVYGVTKEIRQIRLRLFHVA 311
          YVP IGLS+VHRF + V++ +IYLL+PPV+NPI+YG KTK+IR R+L +F ++
GPCR: 251 YVPLIGLSVVHRFGNSLHPVIRVVMGDIYLLLPVINPIIYGAKTKQIRTRVLAMFKIS 309

```

101P3A41

Figure 25: Alignment with human olfactory receptor 5l12 (gi|14423836)

Identities = 163/304 (53%), Positives = 214/304 (69%), Gaps = 1/304 (0%)

```

PHOR: 7  NESSATYFILIGLPGLEEAQFWLAFPLCSLYLIAVLGNLTIIYIVRTEHSLHEPMYIFLC 66
      N +  +F+L G+PGL E +  WL+ PLC +Y +A+ GN  I+  VR E SLHEPMY FL
HOR5: 5  NVTHPAFFLLTGIPGLESSHWSLWGPLCVMYAVALGNTVILQAVRVEPSLHEPMMYYFLS 64

PHOR: 67  MLSGIDILISTSSMPKMLAIFWFNSTTIQFDACLLQIFAIHSLSGMESTVLLAMAFDRYV 126
      MLS D+ IS +++P +L  F  N+  I FDACL+Q+F IH  S MES +LLAM+FDYRV
HOR5: 65  MLSFSDVAISMATLPTVLRTFCLNARNITFDACLIQMFLIHFFSMMESGILLAMSFDYRV 124

PHOR: 127  AICHPLRHATVLTLPVTKIGVAAVVRGAALMAPLPVFIKQLPFCRSNILSHSYCLHQDV 186
      AIC PLR+ATVLT  +  +G+ A  R  +  PLP  IK+LP CRSN+LSHSYCLH D+
HOR5: 125  AICDPLRYATVLTTEVIAAMGLGAAARSFITLFPLPFLIKRLPICRSNVLSHSYCLHPDM 184

PHOR: 187  MKLACDDIRVNVVYGLIVIIISAIGLDSLLISFSYLLILKTVLGL-TREAQAKAFGTCVSH 245
      M+LAC DI +N +YGL V++S  G+D  I  SY+LIL++V+  +RE + KA  TCVSH
HOR5: 185  MRLACADISINSIYGLFVLVSTFGMDLFFIFLSYVLILRSVMATASREERLKA LNTCVSH 244


PHOR: 246  VCAVFIFYVPFIFGLSMVHRFSKRRDSPLPVILANIYLLVPPVLNPIVYGVTKEIRQRIL 305
      + AV  FYVP IG+S VHRF K  + V+++N+YL VPPVLNP++Y  KTKAIR+ I
HOR5: 245  ILAVLAFYVPMIGVSTVHRFGKHVPCYIHVLMNSNVYLFVPPVLNPLIYSAKTKEIRRAIF 304

PHOR: 306  RLFH 309
      R+FH
HOR5: 305  RMFH 308

```




Figure 26: 101P3A11 Modulated Tyrosine Phosphorylation in NIH-3T3 Cells




- 101P3A11 mediated the de-phosphorylation of proteins at 200, 120-140, 85-90 and 55 kDa
- 101P3A11 induced the phosphorylation of proteins at 80 and 29 kDa in NIH-3T3 cells.

Figures 27A-27B: ERK Phosphorylation by PCR Ligands in 101P3A11  
Expressing Cells




•FBS, lipophosphatidic acid, gastrin releasing peptide, leukotriene and platelet activating factor induced the phosphorylation of ERK in 101P3A11 expressing cells.

Figure 28: Inhibition of 101P3A11-Mediated ERK Activation by PD98059




•ERK phosphorylation was inhibited by a MEK specific(PD98059) but not a p38 specific (SB203580) inhibitor in PC3-101P3A11 cells.

Figure 29: Enhanced ERK Phosphorylation in Sodium Orthovanadate Treated PC3-101P3A11 Cells




•Sodium orthovanadate induced increased ERK phosphorylation in PC3-101P3A11 cells relative to PC3-neo cells.

Figure 30: Inhibition of 101P3A11-Mediated ERK Phosphorylation  
by AG1517



- The EGFR inhibitor, AG1517, inhibits EGF-mediated ERK phosphorylation in control and 101P3A11 expressing PC3 cells.
- AG1517 partially inhibits 101P3A11 mediated ERK phosphorylation in PC3 cells.

Figure 31A-31B: Activation of p38 in PC3-101P3A11 Cells



•Expression of 101P3A11 mediates p38 phosphorylation in cells treated with 10% FBS.


Figure 32: 101P3A11 Induced Accumulation of cAMP in PC3 Cells

| Fold change in [cAMP] |      |         |          |
|-----------------------|------|---------|----------|
|                       |      | PC3-Neo | PC3-PHOR |
| 0.1%FBS               | -PTX | 1       | 4.302    |
|                       | +PTX | 1.403   | 2.577    |
| 10%FBS                | -PTX | 2.738   | 6.978    |
|                       | +PTX | 2.163   | 2.752    |

Fold Change in cAMP accumulation was calculated  
relative to PC3-neo cells grown in 0.1%FBS

- Expression of 101P3A11 increased the accumulation of cAMP in cells treated with 0.1% and 10% FBS.
- FBS-induced cAMP accumulation in 101P3A11 cells was inhibited by pertussis toxin.


Figure 33: Pertussis Toxin Inhibits 101P3A11 Mediated ERK  
Phosphorylation



•Pertussis toxin inhibited FBS- mediated ERK phosphorylation in 101P3A11  
expressing cells.




Figure 34: Pertussis Toxin Inhibited ERK Phosphorylation in PC3-101P3A11 Cells




- Pertussis toxin inhibited FBS- mediated ERK phosphorylation in 101P3A11 expressing cells.
- The inhibitory activity of pertussis toxin on ERK phosphorylation was more dramatic in FBS-treated than EGF or GRP-treated PC3-101P3A11 cells.

Figure 35: Inhibition of 101P3A11 Mediated Signaling by Suranim




- Control NIH 3T3 and 3T3-101P3A11 cells were grown in the presence of absence of G protein inhibitors suranim and NF449. Proliferation was analyzed by Alamar blue after 72 hours.
- Suranim and NF449 inhibited the proliferation of 101P3A11 expressing but not control cells.

Figures 36A-36B: 101P3A11 Mediated ERK Phosphorylation By  
Conditioned Media




- Supernatants from PC3, PC3-101P3A11, PrEC and LAPC4<sup>2</sup> cells induce ERK phosphorylation in PC3 101P3A11 but not PC3 cells.
- Supernatants from 3T3 and 293T cells had little specific effect on ERK phosphorylation.

Figure 37: 101P3A11 Enhances The Proliferation of 3T3 Cells




- Control NIH 3T3 and 3T3-101P3A11 cells were grown in the presence of absence 0.5 or 10% FBS. Proliferation was analyzed by Alamar blue after 48 hours.
- Expression of 101P3A11 induced a 6 fold increase in the proliferation of 3T3 cells grown in 0.5% FBS.

Figure 38: Inhibition of 101P3A11 Mediated ERK Phosphorylation by 101P3A11 Specific Antibodies



- Expression of 101P3A11 induced ERK phosphorylation in 293T cells.
- Anti-101P3A11 pAb inhibited ERK Phosphorylation in 293T-101P3A11 cells .

Figure 39: Anti-101P3A11 Ab Mediated cAMP Accumulation in PC3-101P3A11 Cells



| Treatment  | Fold Increase in cAMP |             |
|------------|-----------------------|-------------|
|            | PC3                   | PC3-PHOR    |
| 0.1% FBS   | 1+ 0.42               | 5.73 + 0.47 |
| PTX 1ug/ml | 0.74+ 0.28            | 2.12 + 0.09 |
| anti-PHOR  | 0.97+ 0.35            | 4.01+ 0.64  |

- Control PC3 cells and cells expressing 101P3A11 were treated with anti-101P3A11 pAb for 2 min and evaluated for intracellular cAMP content.
- The assay was performed in duplicate.

Figure 40A-40F

Fig. 40A. Prostate Cancer, 400X




Fig. 40D. LNCaP, 400X




Fig. 40B. Prostate Cancer, 400X




Fig. 40E. Prostate, 400X




Fig. 40C. Prostate Cancer, 2000X





Fig. 40F. Prostate, 2000X



Title: NUCLEIC ACID AND CORRESPONDING PROTEIN  
ENTITLED 101P3A41 USEFUL IN TREATMENT AND  
DETECTION OF CANCER

First Inventor: Daniel E. H. AFAR, et al

Application No.: To Be Assigned - Docket No. 511582002420

Sheet 48 of 50

Fig.41A Prostate Cancer, 800X




Fig.41B Bladder Cancer, 800X




Fig.41C Kidney Cancer, 800X




Fig.41D Colon Cancer, 800X




Fig.41E Lung Cancer, 800X




Fig.41F Breast Cancer, 800X




FIG. 41A-41F



Figure 42





Figure 43



Neo

101P3A11

Ras

| Cell Line    | Colony number |  |
|--------------|---------------|--|
|              | Average       |  |
| 3T3-neo      | 0.5           |  |
| 3T3-101P3A11 | 686           |  |
| 3T3-Ras      | 249           |  |